CDT Equity Inc. has redefined its business model into three complementary pathways—pharmaceutical assets, proprietary solid-form IP and AI-driven discovery—aiming to maximize licensing opportunities while minimizing late-stage clinical risk. This approach bundles clinically validated molecules with enhanced formulations and data-driven indication selection to attract upfront payments, milestones and long-term royalties.

The company continues to evaluate and advance AZD1656, AZD5658 and AZD5904, all in-licensed from AstraZeneca with established safety profiles, through combination therapies and novel indications. These assets benefit from extensive clinical validation, providing a strong foundation for partnership discussions and rapid progression into new therapeutic areas.

CDT is expanding its solid-form and cocrystal portfolio to improve physicochemical properties, extend patent life and create differentiated versions of existing compounds. These programs target commercialization with pharmaceutical partners or capital investors seeking late-stage development candidates.

Through its 20% ownership of Sarborg Limited, CDT leverages a proprietary Signature Intelligence platform that performs large-scale biological and chemical signature analyses to identify high-probability disease indications within minutes. This integration enhances asset packages with AI-informed insights and underpins a capital-efficient, out-licensing model generating multiple revenue streams.